Dr. Joseph Pantginis

H.C. Wainwright & Co.

Joseph Pantginis, Ph.D., joined H.C. Wainwright as Managing Director covering Biotechnology. Dr. Pantginis has over 15 years of sell-side experience covering biotechnology companies, having spent most of those years at ROTH Capital Partners and Canaccord Adams. Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he founded the Retrovirus Core Facility, providing molecular biology service and retroviral vectors to a broad range of Regeneron's research programs. His therapeutic focus is oncology, as well as regenerative medicine and gene therapy. He is also widely recognized for his expertise in cancer immunotherapy as a therapeutic approach to treating cancer. Dr. Pantginis received a B.S. in Biology from Fordham University, an M.B.A. in finance from Pace University, and a Ph.D. in Molecular Genetics from the Albert Einstein College of Medicine.

Recent Articles

Approval Sought in Japan for New Drug to Lower Cholesterol 12/03/2024

The U.S. biopharma behind the drug is "pushing for accelerated adoption and expansion into additional territories," noted an H.C. Wainwright & Co. report.

Pharma Stock Has Significant Upside Potential, Analyst Says 11/04/2024

"We believe significant upside potential exists," H.C. Wainwright & Co. analysts wrote about Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) in an updated research note.

New Jersey Biotech Reports Positive Survival Data 10/02/2024

H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price.

Trial Data Help Position Cell Pouch for Commercial Success 09/16/2024

The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report.

Pharma Co. Enrolls First Patient in Trial 09/05/2024

Rigel Pharmaceuticals (RIGL:NASDAQ) recently announced the enrollment of the first patient in a Phase 1b/2 trial assessing decitabine and venetoclax in combination with Rezlidhia in mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), according to an H.C. Wainwright & Co. research note, which rated the stock a Buy.

Biopharma Acquires Royalty on Approved Diabetes Drug 11/03/2023

This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report.

Co. Reaches Major Milestone With Novel Drug 09/07/2023

The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report.